Alvotech Announces That the U.S. FDA and EMA Have Accepted Regulatory Submissions for AVT02, a Proposed Biosimilar to HUMIRA® (adalimumab)
Alvotech is developing AVT02 as a proposed biosimilar to HUMIRA® (adalimumab) with high concentration (100mg/mL)…